Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases. [PDF]
Fang X, Wei R, Zhu W, Hu Y, Liang H.
europepmc +1 more source
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller +16 more
wiley +1 more source
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. [PDF]
Zheng H +15 more
europepmc +1 more source
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti +18 more
wiley +1 more source
PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report. [PDF]
Hua H +7 more
europepmc +1 more source
Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley +1 more source
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama +16 more
wiley +1 more source
CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development. [PDF]
Chen Q +6 more
europepmc +1 more source

